Brief: OSE Immunotherapeutics Announces First Clinical Results For BI 770371
23/10/2023 20:30
Oct 23 (Reuters) - OSE Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS ANNOUNCES FIRST CLINICAL RESULTS FOR BI 770371, A
NOVEL
ANTI-SIRPΑ MONOCLONAL ANTIBODY
Source text for Eikon: ID:nBw2gQ51da
Further company coverage: OSE.PA
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO